Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...
Yahoo Finance25d
Biogen buys rights to Stoke’s rare epilepsy drug
Biogen on Tuesday agreed to pay $165 million ... The Stifel team spoke to physicians, who were clear that the efficacy bar zorevunersen needs to meet is “very high.” ...
The Business Journals1mon
Biogen details pipeline culling as it looks for more deals like HI-Bio acquisition
Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.